Switch to:
Also traded in: France, Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.42
IPSEY's Cash-to-Debt is ranked higher than
65% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. IPSEY: 1.42 )
Ranked among companies with meaningful Cash-to-Debt only.
IPSEY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 13.26 Max: 56.44
Current: 1.42
0.1
56.44
Equity-to-Asset 0.56
IPSEY's Equity-to-Asset is ranked lower than
61% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. IPSEY: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
IPSEY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.62 Max: 0.66
Current: 0.56
0.28
0.66
Interest Coverage 67.28
IPSEY's Interest Coverage is ranked lower than
59% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. IPSEY: 67.28 )
Ranked among companies with meaningful Interest Coverage only.
IPSEY' s Interest Coverage Range Over the Past 10 Years
Min: 23.39  Med: 58.38 Max: 203.33
Current: 67.28
23.39
203.33
Piotroski F-Score: 7
Altman Z-Score: 6.59
Beneish M-Score: -2.71
WACC vs ROIC
5.58%
20.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 18.23
IPSEY's Operating Margin % is ranked higher than
77% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. IPSEY: 18.23 )
Ranked among companies with meaningful Operating Margin % only.
IPSEY' s Operating Margin % Range Over the Past 10 Years
Min: 6  Med: 16.24 Max: 21.02
Current: 18.23
6
21.02
Net Margin % 13.52
IPSEY's Net Margin % is ranked higher than
75% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. IPSEY: 13.52 )
Ranked among companies with meaningful Net Margin % only.
IPSEY' s Net Margin % Range Over the Past 10 Years
Min: -2.19  Med: 12.2 Max: 15.2
Current: 13.52
-2.19
15.2
ROE % 17.66
IPSEY's ROE % is ranked higher than
79% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. IPSEY: 17.66 )
Ranked among companies with meaningful ROE % only.
IPSEY' s ROE % Range Over the Past 10 Years
Min: -2.93  Med: 16.33 Max: 19.51
Current: 17.66
-2.93
19.51
ROA % 10.25
IPSEY's ROA % is ranked higher than
78% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. IPSEY: 10.25 )
Ranked among companies with meaningful ROA % only.
IPSEY' s ROA % Range Over the Past 10 Years
Min: -1.75  Med: 9.88 Max: 11.91
Current: 10.25
-1.75
11.91
ROC (Joel Greenblatt) % 62.84
IPSEY's ROC (Joel Greenblatt) % is ranked higher than
89% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. IPSEY: 62.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IPSEY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 18.32  Med: 53.87 Max: 73.38
Current: 62.84
18.32
73.38
3-Year Revenue Growth Rate 9.50
IPSEY's 3-Year Revenue Growth Rate is ranked higher than
59% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. IPSEY: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IPSEY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.4  Med: 5.3 Max: 9.5
Current: 9.5
-1.4
9.5
3-Year EBITDA Growth Rate 13.40
IPSEY's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. IPSEY: 13.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IPSEY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -15.9  Med: 3.8 Max: 21.8
Current: 13.4
-15.9
21.8
3-Year EPS without NRI Growth Rate 17.10
IPSEY's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. IPSEY: 17.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IPSEY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -78.3  Med: -5.95 Max: 28.7
Current: 17.1
-78.3
28.7
GuruFocus has detected 6 Warning Signs with Ipsen SA $IPSEY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IPSEY's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IPSEY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:APNHF, NYSE:PRGO, OTCPK:HLUYY, OTCPK:ORINY, OTCPK:MTZXF, OTCPK:GZPHY, NYSE:RDY, OTCPK:HYPMY, OTCPK:ESALF, OTCPK:MKGAY, NYSE:PTHN, OTCPK:STDAF, NYSE:CTLT, NYSE:VRX, NYSE:MNK, NYSE:TARO, NAS:AKRX, OTCPK:SGIOF, NAS:OPK, NAS:ENDP » details
Traded in other countries:IPNNV.France, I7G.Germany, 0MH6.UK,
Headquarter Location:France
Ipsen SA is a biotechnology specialty care company that produces drugs for uro-oncology, endocrinology, neurology and hematology and primary care.

Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: specialty care and primary care. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focuses on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ratios

vs
industry
vs
history
PE Ratio 40.10
IPSEY's PE Ratio is ranked lower than
60% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. IPSEY: 40.10 )
Ranked among companies with meaningful PE Ratio only.
IPSEY' s PE Ratio Range Over the Past 10 Years
Min: 12.7  Med: 21.78 Max: 2433
Current: 40.1
12.7
2433
Forward PE Ratio 25.06
IPSEY's Forward PE Ratio is ranked lower than
84% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. IPSEY: 25.06 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 40.10
IPSEY's PE Ratio without NRI is ranked lower than
60% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. IPSEY: 40.10 )
Ranked among companies with meaningful PE Ratio without NRI only.
IPSEY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.77  Med: 21.89 Max: 40.9
Current: 40.1
12.77
40.9
Price-to-Owner-Earnings 57.34
IPSEY's Price-to-Owner-Earnings is ranked lower than
68% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. IPSEY: 57.34 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IPSEY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.51  Med: 28.81 Max: 58.49
Current: 57.34
10.51
58.49
PB Ratio 6.64
IPSEY's PB Ratio is ranked lower than
76% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. IPSEY: 6.64 )
Ranked among companies with meaningful PB Ratio only.
IPSEY' s PB Ratio Range Over the Past 10 Years
Min: 1.53  Med: 3.09 Max: 6.77
Current: 6.64
1.53
6.77
PS Ratio 5.42
IPSEY's PS Ratio is ranked lower than
65% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. IPSEY: 5.42 )
Ranked among companies with meaningful PS Ratio only.
IPSEY' s PS Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.61 Max: 5.52
Current: 5.42
1.26
5.52
Price-to-Operating-Cash-Flow 28.45
IPSEY's Price-to-Operating-Cash-Flow is ranked lower than
66% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. IPSEY: 28.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IPSEY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.61  Med: 14.03 Max: 29.03
Current: 28.45
6.61
29.03
EV-to-EBIT 29.38
IPSEY's EV-to-EBIT is ranked higher than
93% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. IPSEY: 29.38 )
Ranked among companies with meaningful EV-to-EBIT only.
IPSEY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 16 Max: 30.1
Current: 29.38
8.7
30.1
EV-to-EBITDA 26.03
IPSEY's EV-to-EBITDA is ranked higher than
92% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. IPSEY: 26.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
IPSEY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 11.85 Max: 26.6
Current: 26.03
7.3
26.6
PEG Ratio 2.30
IPSEY's PEG Ratio is ranked higher than
50% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.90 vs. IPSEY: 2.30 )
Ranked among companies with meaningful PEG Ratio only.
IPSEY' s PEG Ratio Range Over the Past 10 Years
Min: 1.28  Med: 4.14 Max: 37.18
Current: 2.3
1.28
37.18
Shiller PE Ratio 68.11
IPSEY's Shiller PE Ratio is ranked lower than
62% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. IPSEY: 68.11 )
Ranked among companies with meaningful Shiller PE Ratio only.
IPSEY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 1.83  Med: 34.84 Max: 69.35
Current: 68.11
1.83
69.35
Current Ratio 1.87
IPSEY's Current Ratio is ranked lower than
62% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. IPSEY: 1.87 )
Ranked among companies with meaningful Current Ratio only.
IPSEY' s Current Ratio Range Over the Past 10 Years
Min: 1.39  Med: 1.87 Max: 2.33
Current: 1.87
1.39
2.33
Quick Ratio 1.67
IPSEY's Quick Ratio is ranked lower than
54% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. IPSEY: 1.67 )
Ranked among companies with meaningful Quick Ratio only.
IPSEY' s Quick Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.58 Max: 2.03
Current: 1.67
1.08
2.03
Days Inventory 114.81
IPSEY's Days Inventory is ranked higher than
51% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. IPSEY: 114.81 )
Ranked among companies with meaningful Days Inventory only.
IPSEY' s Days Inventory Range Over the Past 10 Years
Min: 114  Med: 159.26 Max: 176.3
Current: 114.81
114
176.3
Days Sales Outstanding 73.13
IPSEY's Days Sales Outstanding is ranked lower than
52% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. IPSEY: 73.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPSEY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.7  Med: 73.48 Max: 80.25
Current: 73.13
66.7
80.25
Days Payable 201.15
IPSEY's Days Payable is ranked higher than
93% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. IPSEY: 201.15 )
Ranked among companies with meaningful Days Payable only.
IPSEY' s Days Payable Range Over the Past 10 Years
Min: 172.18  Med: 191.1 Max: 217.39
Current: 201.15
172.18
217.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.79
IPSEY's Dividend Yield % is ranked lower than
58% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. IPSEY: 0.79 )
Ranked among companies with meaningful Dividend Yield % only.
IPSEY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.76  Med: 2.02 Max: 4.36
Current: 0.79
0.76
4.36
Dividend Payout Ratio 0.32
IPSEY's Dividend Payout Ratio is ranked higher than
58% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. IPSEY: 0.32 )
Ranked among companies with meaningful Dividend Payout Ratio only.
IPSEY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.4 Max: 0.91
Current: 0.32
0.31
0.91
3-Year Dividend Growth Rate 2.00
IPSEY's 3-Year Dividend Growth Rate is ranked lower than
66% of the 285 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. IPSEY: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
IPSEY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.1 Max: 7.7
Current: 2
0
7.7
Forward Dividend Yield % 0.79
IPSEY's Forward Dividend Yield % is ranked lower than
60% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. IPSEY: 0.79 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.85
IPSEY's 5-Year Yield-on-Cost % is ranked lower than
66% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. IPSEY: 0.85 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
IPSEY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.81  Med: 2.17 Max: 4.67
Current: 0.85
0.81
4.67
3-Year Average Share Buyback Ratio 0.20
IPSEY's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. IPSEY: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPSEY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.1  Med: 0.15 Max: 0.9
Current: 0.2
-42.1
0.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 14.49
IPSEY's Price-to-Tangible-Book is ranked lower than
86% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. IPSEY: 14.49 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IPSEY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.1  Med: 5.95 Max: 14.62
Current: 14.49
3.1
14.62
Price-to-Intrinsic-Value-Projected-FCF 4.01
IPSEY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
58% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. IPSEY: 4.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IPSEY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.84  Med: 1.53 Max: 4.04
Current: 4.01
0.84
4.04
Price-to-Median-PS-Value 2.07
IPSEY's Price-to-Median-PS-Value is ranked lower than
80% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. IPSEY: 2.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IPSEY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 0.95 Max: 2.09
Current: 2.07
0.57
2.09
Price-to-Peter-Lynch-Fair-Value 2.28
IPSEY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
60% of the 174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. IPSEY: 2.28 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IPSEY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.41  Med: 1.63 Max: 3.27
Current: 2.28
1.41
3.27
Price-to-Graham-Number 5.09
IPSEY's Price-to-Graham-Number is ranked lower than
79% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. IPSEY: 5.09 )
Ranked among companies with meaningful Price-to-Graham-Number only.
IPSEY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.18  Med: 2.32 Max: 5.13
Current: 5.09
0.18
5.13
Earnings Yield (Greenblatt) % 3.41
IPSEY's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. IPSEY: 3.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IPSEY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.3  Med: 6.25 Max: 11.5
Current: 3.41
3.3
11.5
Forward Rate of Return (Yacktman) % 18.56
IPSEY's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. IPSEY: 18.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IPSEY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.3  Med: 5 Max: 19.3
Current: 18.56
-5.3
19.3

More Statistics

Revenue (TTM) (Mil) $1,818
EPS (TTM) $ 0.75
Beta0.76
Short Percentage of Float0.00%
52-Week Range $14.15 - 30.88
Shares Outstanding (Mil)329.72

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,188 2,427 2,652
EPS ($) 1.19 1.34 1.52
EPS without NRI ($) 1.19 1.34 1.52
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.47 0.53 0.60
» More Articles for IPSEY

Headlines

Articles On GuruFocus.com
Wasatch International Growth Fund Comments on Ipsen S.A. Sep 25 2015 
Wasatch International Growth Fund Q2 2015 Shareholder Letter Sep 25 2015 

More From Other Websites
Ipsen Presents Its New Strategy and Improved 2020 Financial Targets May 11 2017
Ipsen Completes Acquisition of Select Consumer Healthcare Products from Sanofi May 08 2017
Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1 Apr 27 2017
Commercial Vehicle Group, MTS Systems, Ipsen, AXA and Arkema highlighted as Zacks Bull and Bear of... Apr 26 2017
Resolutions Submitted to Ipsen’s Shareholders’ Meeting on June 7, 2017 Apr 25 2017
French Stocks at 2-Year High on Macron Lead: 4 Picks Apr 25 2017
Ipsen Biopharmaceuticals, Inc. Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA)... Apr 19 2017
Ipsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer Apr 14 2017
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology... Apr 03 2017
The U.S.A. and China Start Talking: Global Week Ahead Apr 03 2017
Ipsen SA :IPSEY-US: Earnings Analysis: For the six months ended December 31, 2016 : April 3, 2017 Apr 03 2017
Ipsen Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the... Mar 14 2017
Ipsen announces MHRA1 approval of new indication for Decapeptyl® for the treatment of... Mar 13 2017
Ipsen Announces Data Presentations of Lanreotide (Somatuline® Autogel®), Telotristat Ethyl and the... Mar 09 2017
Ipsen Appoints Benoit Hennion as Executive Vice President and President, Primary Care Mar 02 2017
UPDATE 1-FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug Feb 28 2017
Ipsen SA :IPSEY-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017 Feb 28 2017
Ipsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017 Feb 23 2017
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi Feb 13 2017
Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg Feb 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)